Induction of Antitumor Immunity Ex Vivo Using Dendritic Cells Transduced with Fowl Pox Vector Expressing MUC1, CEA, and a Triad of Costimulatory Molecules (rF-PANVAC)
Overview
Authors
Affiliations
The fowl pox vector expressing the tumor-associated antigens, mucin-1 and carcinoembryonic antigen in the context of costimulatory molecules (rF-PANVAC) has shown promise as a tumor vaccine. However, vaccine-mediated expansion of suppressor T-cell populations may blunt clinical efficacy. We characterized the cellular immune response induced by ex vivo dendritic cells (DCs) transduced with (rF)-PANVAC. Consistent with the functional characteristics of potent antigen-presenting cells, rF-PANVAC-DCs demonstrated strong expression of mucin-1 and carcinoembryonic antigen and costimulatory molecules, CD80, CD86, and CD83; decreased levels of phosphorylated STAT3, and increased levels of Tyk2, Janus kinase 2, and STAT1. rF-PANVAC-DCs stimulated expansion of tumor antigen-specific T cells with potent cytolytic capacity. However, rF-PANVAC-transduced DCs also induced the concurrent expansion of FOXP3 expressing CD4CD25 regulatory T cells (Tregs) that inhibited T-cell activation. Moreover, Tregs expressed high levels of Th2 cytokines [interleukin (IL)-10, IL-4, IL-5, and IL-13] together with phosphorylated STAT3 and STAT6. In contrast, the vaccine-expanded Treg population expressed high levels of Th1 cytokines IL-2 and interferon-γ and the proinflammatory receptor-related orphan receptor γt (RORγt) and IL-17A suggesting that these cells may share effector functions with conventional TH17 T cells. These data suggest that Tregs expanded by rF-PANVAC-DCs, exhibit immunosuppressive properties potentially mediated by Th2 cytokines, but simultaneous expression of Th1 and Th17-associated factors suggests a high degree of plasticity.
Cigarette Smoke and Morphine Promote Treg Plasticity to Th17 via Enhancing Trained Immunity.
Shao Y, Saaoud F, Cornwell W, Xu K, Kirchhoff A, Lu Y Cells. 2022; 11(18).
PMID: 36139385 PMC: 9497420. DOI: 10.3390/cells11182810.
Escher T, Lui A, Geanes E, Walter K, Tawfik O, Hagan C Mol Cancer Res. 2019; 17(5):1180-1194.
PMID: 30655323 PMC: 6497545. DOI: 10.1158/1541-7786.MCR-18-0916.
Dillon P, Petroni G, Smolkin M, Brenin D, Chianese-Bullock K, Smith K J Immunother Cancer. 2017; 5(1):92.
PMID: 29157306 PMC: 5697108. DOI: 10.1186/s40425-017-0295-5.
Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment.
Yu S, Ballas L, Skinner E, Dorff T, Sadeghi S, Quinn D Clin Adv Hematol Oncol. 2017; 15(7):543-551.
PMID: 28749918 PMC: 7523177.
Enhancing poxvirus vectors vaccine immunogenicity.
Garcia-Arriaza J, Esteban M Hum Vaccin Immunother. 2014; 10(8):2235-44.
PMID: 25424927 PMC: 4896794. DOI: 10.4161/hv.28974.